KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything
āļāļąāļ
- āđāļāļĒāđāļāļĢāđāđāļĄāļ·āđāļ 27 āļ.āļ. 2024
- FDA Just Approved KarXT - Is This the Future of Schizophrenia Treatment?
ðSubscribe to Newsletter: www.thecarlatr...
ð§Full Podcast: podcasts.apple...
ðMedication Fact Book: www.thecarlatr...
================
Follow Carlat:
ðīSUBSCRIBE âš / @thecarlatreport
âĄïļTwitter: / CarlatPsych
================
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesnât rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
We'll start by explaining the science behind KarXT and how its combination of Xanomeline and Trospium works together to provide effective symptom control while reducing many of the typical side effects seen in older medications. The benefits of KarXT go beyond just managing symptoms-its novel mechanism means patients may experience fewer issues like weight gain, fatigue, and extrapyramidal symptoms that are common with older antipsychotics. Weâll discuss what this Cobenfy approval means for patients and the potential impact it could have on psychiatric care moving forward.
Weâll also cover the side effects of KarXT, including both the cholinergic and anticholinergic effects that you might expect from this type of medication. While KarXT may offer fewer of the traditional side effects, it does come with its own considerations, such as dry mouth, constipation, and nausea. Plus, weâll look into how Cobenfy compares to traditional dopamine-blocking antipsychotics and what clinicians should keep in mind when prescribing it.
This video also touches on why the KarXT efficacy trials have generated so much excitement in the psychiatric community. The EMERGENT trials, which tested KarXT for schizophrenia, showed promising results with fewer discontinuations due to side effects compared to placebo. Weâll explain what these results mean and why Cobenfy for schizophrenia treatment could be a major advancement in the field of psychopharmacology.
If youâre interested in the future of mental health treatment or if youâre a healthcare professional looking to stay updated on the latest developments, this video will give you a thorough overview of KarXT, its unique approach, and how it stands out from other antipsychotics on the market. Weâll also share our thoughts on what this Cobenfy approval means for patients and whether KarXT could be the future of antipsychotic medication.
By the end of this video, youâll have a clear understanding of the benefits of KarXT, how it works, what to watch for in terms of KarXT side effects, and why this drug is considered a significant breakthrough in schizophrenia treatment.
Helpful and educational, as always!
Thanks!
reducing/eliminating risk of drug-induced movement disorders can be viewed as game changing
True!
Beautiful video!
Thank you very much!
Great video! Easy to understand and informative.
I shall always like your videos. It is exciting to have a newer mechanism of action in the market but I am hesitant to prescribe it until we have independent RTCs
Appreciate it! We agree.
Sounds like it could be a good tool, BID dosing with schizophrenics patients does sound daunting though
BID pales to side-effects though!
Cobenfy tablet When will come in India sir
Hello bro are you suffering from schizophrenia? I suffer from it.